NewAmsterdam Pharma Company N.V. (NAMS)

In the past six months, NAMS stock has trended upwards. Key events include the February 2026 earnings report, which missed analysts' estimates and led to a stock decrease. Presentations at ACC.26 in March 2026 focused on Obicetrapib data. Truist Financial initiated coverage with a "Buy" rating, while the company has a consensus rating of "Moderate Buy". Heavy insider selling has weighed on sentiment. The European Medicine Agency accepted Marketing Authorization Applications for Obicetrapib in August 2025. The company ended 2025 with approximately $729 million in cash, cash equivalents, and marketable securities.

Information regarding specific demand seasonality for NewAmsterdam Pharma Co. NV's products and services is inconclusive. As a clinical-stage biopharmaceutical company with no approved products or commercial revenue, its current operations are centered on drug discovery, clinical development, and regulatory advancement. The company's focus is on the successful progression of its clinical pipeline and regulatory approvals, which are not typically subject to seasonal fluctuations.

NewAmsterdam Pharma Co. NV is a clinical-stage biopharmaceutical company focused on developing oral therapies for cardiometabolic diseases, particularly dyslipidemia. Their primary product, Obicetrapib, is being investigated in clinical trials for lowering LDL-C in cardiovascular diseases and is also in Phase 2a trials for Alzheimer's disease. The company operates as a single reporting segment focused on pharmaceutical R&D, with no approved products or commercial revenue.

NewAmsterdam Pharma is incorporated in the Netherlands, with legal headquarters in Amsterdam and Naarden. It maintains a significant operational presence in the United States, with executive leadership and clinical development functions based in Florida and Pennsylvania. Clinical trials and research activities are conducted across North America, Europe, and other international regions through contracted sites, supporting future global regulatory submissions.

NewAmsterdam Pharma's brand reputation is tied to its clinical progress and scientific presentations. Positive data from clinical trials, including the BROADWAY and TANDEM studies, have been published in medical journals. The acceptance of Marketing Authorization Applications by the European Medicine Agency is a positive development. The company has received a "Moderate Buy" consensus rating from analysts. Significant insider selling could raise concerns among investors.

NewAmsterdam Pharma has significant institutional ownership, with 197 institutional owners and shareholders holding a total of 117,984,950 shares. Institutional shareholders hold 103.13% of the stock, while insiders hold 35.40%. Major institutional owners include Frazier Life Sciences Management LP, Capital World Investors, and RA Capital Management, L.P. The largest individual shareholder is James N. Topper.